



PRISMAP NEWS

13 MEDICIS Board

Thierry Stora, CERN

11 Dec 2024



Outcome of 2nd review 4 July

Period covered by the report:	from 01/11/2022 to 30/04/2024
Periodic report/Reporting period number:	2
Date of first submission of the periodic report (if applicable):	24/06/2024
Amendments (latest AMD concerning description of the action)²	Not applicable
Date of meeting with consortium (if applicable):	04/07/2024 - 04/07/2024
Name of project officer:	Anna SANTORO
Name(s) of monitors:	– SERGE GOLDMAN • • UNIVERSITE LIBRE DE BRUXELLES

1. Overall assessment

Project has fully achieved its objectives and milestones for the period.

2. Significant results linked to dissemination, exploitation and impact potential

Project has delivered exceptional results with significant immediate or potential impact (even if not all objectives mentioned in the Annex 1 to the GA were achieved).

The most significant result of Prisma during this period is the publication of a high-quality article. First, this result demonstrates the quality of the whole process put in place by the consortium. The publication involves two different partners of Prisma indicating that the consortium is not just the addition of different independent actors. Second, the article is authored by a user of two infrastructures of Prisma selected by the consortium, indicating that the consortium has attracted European high-level research centers. Thirdly, the article compares a classical radioisotope to an innovative one developed and proposed by Prisma. This is the perfect show case of the whole process followed by Prisma. Fourth, the dissemination of the result in the most important journal in nuclear medicine (JNM) ensures the target community will be attracted by the activities of Prisma.

Outcome of 2nd review 4 July - Recommendation

5. Recommendations concerning future work, if applicable

Globally, the consortium goes in the right direction so that there is no major change to recommend in order to improve the strategy and the general conduct of the activities.

Still, there are some recommendations to make in order to increase the chances for the consortium to reach its objectives.

1. Sustainability of PRISMAP requires that the consortium establishes itself as spearheading research into the development of new radioisotopes. This should be the way industry consider the infrastructure. A recommendation is that Prisma interacts more actively with the industrial/commercial actors in the radiopharmaceutical domains to appear as this necessary partner for the appearance of innovative radioisotopes for medical use. Partnership with the industry is the only way for the products of Prisma to reach the market and get its expected societal impact. At this stage, the industry is concentrated on the exploitation of the few radioisotopes that are currently available; it is necessary for Prisma to demonstrate the benefits inherent to the new radioisotopes it proposes. It is crucial to work on the demonstration of these benefits, in comparison to classical radioisotopes, in terms of radiobiology and imaging/therapeutic potential in preclinical experiments. Prisma needs to proactively generate interest in its isotopes among potential academic users, or boost internally the necessary demonstration, as already done in WP11-JRA3 at UiO.

2. As planned in the proposal (see MS5), it is recommended to have at least on high-quality clinical trial performed

Projects highlighted

- Only 2 projects are aiming to get translated to the clinical phase :
- P4 and P21 / stay tuned : reports will be provided this morning in the context of MED-032 (PRISMAP - P23 project):

203/212Pb-mcp-D-PSMA for an improved tumor therapy: Preclinical evaluation, automatization and translation to clinical application and

PRISMAP objectives

- Provide access to new radionuclides and new purity grades for medical research
Ongoing
- Create a common entry port and web interface for the starting research community
Ongoing
- Enhance clarity and regulatory procedures to promote research with radiopharmaceuticals
Ongoing
- Unlock the biomedical research through better data on radionuclides
Ongoing
- *Ensure the long-term sustainability of PRISMAP (PRISMAP-PLUS)
Started (CM5, exec summary, ERVI stakeholder meeting, policy input)*

PRISMAP + announced as a targeted call in INFRADEV-20215-1 !

- Announced by our Project Officer at CERN on 25 Sept:

CERN hosted the 21st Plenary Meeting of the European Observatory on the the Supply of Medical Radionuclides on 25 and 26 of September 2024.



Call open 1st May 2025 – Subm. Sept 2025

Prep meeting held in Nantes :

55 participants

5 Mi Euro overall budget

<https://indico.cern.ch/event/1438450/>

Intended to (slightly) extend the scope (geographical and thematic nodes, and geographical cover)

2 emerging facilities made their 1st radionuclides : SPIRAL 2, SPES

Launch a Marie Curie ITN InnoMedRab – lead prof Cocolios

Involved in the ERVI process driven by DG-ENER:

Aiming at a high level committee which will discuss the follow-up of PRISMAP + in the next multiannual Financial Framework (MFF) 2028-2034